Business Description
Lotus Pharmaceuticals
NAICS : 551112
SIC : 6719
ISIN : US5457152032
Description
Lotus Pharmaceuticals is a development stage company.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Equity-to-Asset | -53.5 | |||||
| Debt-to-Equity | -1.02 | |||||
| Debt-to-EBITDA | -27.25 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 1045.57 | |||||
| Beneish M-Score | -9704.36 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -19.6 | |||||
| 3-Year EBITDA Growth Rate | -19.3 | |||||
| 3-Year EPS without NRI Growth Rate | -6.5 | |||||
| 3-Year FCF Growth Rate | 3.7 | |||||
| 3-Year Book Growth Rate | 38.3 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 70.48 | |||||
| 9-Day RSI | 52.02 | |||||
| 14-Day RSI | 47.01 | |||||
| 6-1 Month Momentum % | 27.04 | |||||
| 12-1 Month Momentum % | -30 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.02 | |||||
| Quick Ratio | 0.02 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -8.1 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| FCF Margin % | -3.68 | |||||
| ROA % | -200 | |||||
| ROIC % | -3.67 | |||||
| ROC (Joel Greenblatt) % | -200 | |||||
| Years of Profitability over Past 10-Year | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | N/A |
N/A
|
N/A
| |||
| PE Ratio without NRI | N/A |
N/A
|
N/A
| |||
| Price-to-Operating-Cash-Flow | 0.01 | |||||
| EV-to-EBIT | -60 | |||||
| EV-to-EBITDA | -60 | |||||
| EV-to-FCF | -0.09 | |||||
| Earnings Yield (Greenblatt) % | -1.67 | |||||
| FCF Yield % | -2040.46 | |||||
| Forward Rate of Return (Yacktman) % | 6756.43 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:LTUS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Lotus Pharmaceuticals Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 72.697 | ||
| EPS (TTM) ($) | 0 | ||
| Beta | 0.64 | ||
| Volatility % | 81.65 | ||
| 14-Day RSI | 47.01 | ||
| 14-Day ATR ($) | 0.000173 | ||
| 20-Day SMA ($) | 0.004663 | ||
| 12-1 Month Momentum % | -30 | ||
| 52-Week Range ($) | 0.0035 - 0.012 | ||
| Shares Outstanding (Mil) | 27.82 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Lotus Pharmaceuticals Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Lotus Pharmaceuticals Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Lotus Pharmaceuticals Frequently Asked Questions
What is Lotus Pharmaceuticals(LTUS)'s stock price today?
The current price of LTUS is $0.00. The 52 week high of LTUS is $0.01 and 52 week low is $0.00.
When is next earnings date of Lotus Pharmaceuticals(LTUS)?
The next earnings date of Lotus Pharmaceuticals(LTUS) is .
Does Lotus Pharmaceuticals(LTUS) pay dividends? If so, how much?
Lotus Pharmaceuticals(LTUS) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers